ALLO

ALLO

Allogene Therapeutics Inc. Common Stock

$1.400+0.000 (0.000%)

Prix en Temps Réel

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$1.400

Haut

$1.400

Bas

$1.400

Volume

1.76M

Fondamentaux de l'Entreprise

Statistiques de Trading

Actualités Connexes

GlobeNewswire

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)

Voir plus
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
GlobeNewswire

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™)

Voir plus
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
Analyst Upgrades

Citigroup Maintains Buy on Allogene Therapeutics, Lowers Price Target to $4

Citigroup analyst Samantha Semenkow maintains Allogene Therapeutics with a Buy and lowers the price target from $8 to $4.

Voir plus
Citigroup Maintains Buy on Allogene Therapeutics, Lowers Price Target to $4
Analyst Upgrades

Truist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $10

Truist Securities analyst Asthika Goonewardene maintains Allogene Therapeutics with a Buy and lowers the price target from $14 to $10.

Voir plus
Truist Securities Maintains Buy on Allogene Therapeutics, Lowers Price Target to $10
Analyst Upgrades

Piper Sandler Maintains Overweight on Allogene Therapeutics, Lowers Price Target to $7

Piper Sandler analyst Biren Amin maintains Allogene Therapeutics with a Overweight and lowers the price target from $9 to $7.

Voir plus
Piper Sandler Maintains Overweight on Allogene Therapeutics, Lowers Price Target to $7
Analyst Upgrades

RBC Capital Reiterates Outperform on Allogene Therapeutics, Maintains $10 Price Target

RBC Capital analyst Luca Issi reiterates Allogene Therapeutics with a Outperform and maintains $10 price target.

Analyst Upgrades

Oppenheimer Maintains Outperform on Allogene Therapeutics, Lowers Price Target to $9

Oppenheimer analyst Matthew Biegler maintains Allogene Therapeutics with a Outperform and lowers the price target from $10 to $9.